Min‐Hee Ryu

20.0k total citations · 3 hit papers
327 papers, 7.6k citations indexed

About

Min‐Hee Ryu is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Gastroenterology. According to data from OpenAlex, Min‐Hee Ryu has authored 327 papers receiving a total of 7.6k indexed citations (citations by other indexed papers that have themselves been cited), including 228 papers in Pulmonary and Respiratory Medicine, 150 papers in Oncology and 116 papers in Gastroenterology. Recurrent topics in Min‐Hee Ryu's work include Gastric Cancer Management and Outcomes (194 papers), Gastrointestinal Tumor Research and Treatment (115 papers) and Colorectal Cancer Treatments and Studies (74 papers). Min‐Hee Ryu is often cited by papers focused on Gastric Cancer Management and Outcomes (194 papers), Gastrointestinal Tumor Research and Treatment (115 papers) and Colorectal Cancer Treatments and Studies (74 papers). Min‐Hee Ryu collaborates with scholars based in South Korea, United States and Japan. Min‐Hee Ryu's co-authors include Yoon‐Koo Kang, Baek‐Yeol Ryoo, Jae‐Lyun Lee, Tae Won Kim, Heung Moon Chang, Hyun Cheol Chung, Changhoon Yoo, Jeong Hwan Yook, Yung‐Jue Bang and Young Soo Park and has published in prestigious journals such as New England Journal of Medicine, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Min‐Hee Ryu

307 papers receiving 7.4k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer

2020 802 citations Kohei Shitara, Yung‐Jue Bang et al. profile →
Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300

2018 372 citations Lucjan Wyrwicz, Min‐Hee Ryu et al. Annals of Oncology profile →
Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4)

2018 228 citations Min‐Hee Ryu, Hyun Cheol Chung et al. Annals of Oncology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Min‐Hee Ryu	4.5k	3.7k	2.4k	2.2k	847	327	7.6k
Vladimir Moiseyenko	4.1k 0.9×	5.6k 1.5×	1.8k 0.7×	1.1k 0.5×	1.0k 1.2×	142	8.1k
Yoshito Komatsu	3.5k 0.8×	4.1k 1.1×	2.2k 0.9×	1.1k 0.5×	984 1.2×	319	6.6k
Toshiharu Yamaguchi	8.6k 1.9×	4.7k 1.3×	6.4k 2.6×	4.0k 1.8×	1.0k 1.2×	368	13.1k
Salah‐Eddin Al‐Batran	3.3k 0.7×	3.2k 0.9×	1.9k 0.8×	1.2k 0.5×	801 0.9×	214	5.6k
Joan Maurel	3.9k 0.9×	6.9k 1.9×	2.5k 1.0×	1.1k 0.5×	1.2k 1.5×	221	9.4k
Scott A. Hundahl	4.3k 1.0×	1.7k 0.5×	3.3k 1.4×	1.9k 0.8×	663 0.8×	42	7.4k
Do Hoon Lim	2.8k 0.6×	1.5k 0.4×	1.7k 0.7×	771 0.3×	376 0.4×	206	5.1k
Akira Sawaki	7.4k 1.6×	6.3k 1.7×	4.7k 1.9×	3.0k 1.3×	1.9k 2.3×	150	11.8k
Jörg T. Hartmann	2.7k 0.6×	3.4k 0.9×	2.1k 0.9×	593 0.3×	762 0.9×	69	5.8k
Young Suk Park	2.3k 0.5×	4.0k 1.1×	1.9k 0.8×	436 0.2×	1.3k 1.5×	227	6.3k

Countries citing papers authored by Min‐Hee Ryu

Since Specialization

Citations

This map shows the geographic impact of Min‐Hee Ryu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Min‐Hee Ryu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Min‐Hee Ryu more than expected).

Fields of papers citing papers by Min‐Hee Ryu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Min‐Hee Ryu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Min‐Hee Ryu. The network helps show where Min‐Hee Ryu may publish in the future.

Co-authorship network of co-authors of Min‐Hee Ryu

This figure shows the co-authorship network connecting the top 25 collaborators of Min‐Hee Ryu. A scholar is included among the top collaborators of Min‐Hee Ryu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Min‐Hee Ryu. Min‐Hee Ryu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Oh, D-Y., Min‐Hee Ryu, Emiliano Calvo, et al.. (2024). 656P Phase I/Ib open-label study of an HER2-targeted T cell engager (TCE)‒SAR443216 in patients (pts) with advanced solid tumors: Intravenous (IV) dose-escalation results. Annals of Oncology. 35. S518–S518.

Chae, Heejung, et al.. (2024). Prognostic value of mismatch repair deficiency in patients receiving first-line fluoropyrimidine plus platinum for metastatic, recurrent, or unresectable gastric cancer. Gastric Cancer. 27(4). 811–818. 1 indexed citations

Kim, Hyung‐Don, et al.. (2024). Impact of systemic steroids on the efficacy of first line imatinib treatment of patients with advanced gastrointestinal stromal tumors (GISTs). BMC Cancer. 24(1). 1245–1245.

Kim, Hyung‐Don, Jinho Shin, In Hye Song, et al.. (2024). Discordant PD-L1 results between 28–8 and 22C3 assays are associated with outcomes of gastric cancer patients treated with nivolumab plus chemotherapy. Gastric Cancer. 27(4). 819–826. 7 indexed citations

Koo, Dong‐Hoe, Jin Young Kim, Jae‐Joon Kim, et al.. (2024). Abstract CT216: Anti-EGFR in combination with paclitaxel as second-line therapy for gastric cancer with EGFR overexpression. Cancer Research. 84(7_Supplement). CT216–CT216. 1 indexed citations

Chae, Heejung, Harim Koo, Sun Young Kim, et al.. (2024). Genomic landscape and therapeutic implications in advanced solid cancers: KOSMOS-II (KOrean Precision Medicine Networking Group Study of MOlecular profiling guided therapy based on genomic alterations in advanced Solid tumors, KCSG AL-22-09).. Journal of Clinical Oncology. 42(16_suppl). 11161–11161.

Kelly, Ronan J., Kensei Yamaguchi, Toshihiro Kudo, et al.. (2024). A randomized, multicenter, open-label, phase 2 study of TRK-950 in combination with ramucirumab and paclitaxel as second-line therapy in patients with Caprin-1 positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.. Journal of Clinical Oncology. 42(16_suppl). TPS4181–TPS4181. 2 indexed citations

Rha, Sun Young, Lucjan Wyrwicz, Yuxian Bai, et al.. (2024). Pembrolizumab (pembro) + chemotherapy (chemo) for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Updated results from the KEYNOTE-859 study.. Journal of Clinical Oncology. 42(16_suppl). 4045–4045. 5 indexed citations

Kim, Hyung‐Don, Ho Yeong Lim, Baek‐Yeol Ryoo, et al.. (2024). Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial. Nature Medicine. 30(3). 699–707. 29 indexed citations

10.

Wyrwicz, Lucjan, Do‐Youn Oh, Yuxian Bai, et al.. (2023). O-3 Additional data from the KEYNOTE-859 study of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer. Annals of Oncology. 34. S181–S181. 3 indexed citations

11.

Kang, Yoon‐Koo, et al.. (2023). Interruption of imatinib in advanced gastrointestinal stromal tumor after prolonged imatinib maintenance in the absence of gross tumor lesions. Gastric Cancer. 26(4). 604–613. 2 indexed citations

12.

Tabernero, Josep, Philippe L. Bédard, Yung‐Jue Bang, et al.. (2023). Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens. Cancer Research Communications. 3(8). 1662–1671. 9 indexed citations

13.

Suh, Koung Jin, Min‐Hee Ryu, Dae Young Zang, et al.. (2023). AZD8186 in Combination With Paclitaxel in Patients With Advanced Gastric Cancer: Results From a Phase Ib/II Study (KCSG ST18-20). The Oncologist. 28(9). e823–e834. 12 indexed citations

14.

Yamaguchi, Kensei, Yung‐Jue Bang, Satoru Iwasa, et al.. (2022). Trastuzumab Deruxtecan in Anti–Human Epidermal Growth Factor Receptor 2 Treatment–Naive Patients With Human Epidermal Growth Factor Receptor 2–Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial. Journal of Clinical Oncology. 41(4). 816–825. 76 indexed citations

15.

Choi, Won‐Mook, Ji Yoon Kim, Jonggi Choi, et al.. (2021). Kinetics of the neutrophil‐lymphocyte ratio during PD‐1 inhibition as a prognostic factor in advanced hepatocellular carcinoma. Liver International. 41(9). 2189–2199. 28 indexed citations

16.

Yoo, Changhoon, Hyo Jeong Kang, Min‐Hee Ryu, et al.. (2021). Clinical outcomes of systemic therapy in patients with unresectable or metastatic combined hepatocellular‐cholangiocarcinoma. Liver International. 41(6). 1398–1408. 27 indexed citations

17.

Yoo, Changhoon, Jwa Hoon Kim, Min‐Hee Ryu, et al.. (2021). Clinical Outcomes with Multikinase Inhibitors after Progression on First-Line Atezolizumab plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Multicenter Retrospective Study. Liver Cancer. 10(2). 107–114. 68 indexed citations

18.

Shin, Young‐Kyoung, et al.. (2020). The role of novel fusion genes in human GIST cell lines derived from imatinib-resistant GIST patients: A therapeutic potential of fusion gene. Biochemical and Biophysical Research Communications. 529(3). 699–706. 9 indexed citations

19.

Choi, Won‐Mook, Jonggi Choi, Danbi Lee, et al.. (2020). Regorafenib Versus Nivolumab After Sorafenib Failure: Real‐World Data in Patients With Hepatocellular Carcinoma. Hepatology Communications. 4(7). 1073–1086. 35 indexed citations

20.

Yoo, Changhoon, Min‐Hee Ryu, Byung Woog Kang, et al.. (2010). Cross-Sectional Study of Imatinib Plasma Trough Levels in Patients With Advanced Gastrointestinal Stromal Tumors: Impact of Gastrointestinal Resection on Exposure to Imatinib. Journal of Clinical Oncology. 28(9). 1554–1559. 73 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact